Bank of America initiated coverage on shares of Orphazyme A/S (NASDAQ:ORPH) in a research note issued to investors on Monday morning, The Fly reports. The firm issued a buy rating and a $13.00 price target on the stock.
Separately, Guggenheim began coverage on shares of Orphazyme A/S in a report on Monday. They set a buy rating and a $27.00 price objective on the stock.
ORPH opened at $9.50 on Monday. Orphazyme A/S has a twelve month low of $9.32 and a twelve month high of $11.07.
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis.
Featured Article: What are no-load funds?
Receive News & Ratings for Orphazyme A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orphazyme A/S and related companies with MarketBeat.com's FREE daily email newsletter.